(Company Code 7702)

JMS CO.,LTD.

Financial Statements
for the 2nd Quarter of Fiscal Year Ending March 31, 2026
(From Apr. 1, 2025 to Sep. 30, 2025)

# Summary of consolidated results

November 7, 2025

# Summary of Financial Results

The Bridge to Good Health Care

## Consolidated

**decrease in sales**
**decrease in profit**

| | |
|---|---|
| **Net sales** | **32,216 million yen ((1,614) million yen)** |
| **Operating profit** | **(19) million yen ( (174) million yen)** |

Sales : Although domestic sales in the Oncology and Nutrition fields increased, overseas sales decreased due to reduced orders in the Blood Management & Cell Therapy field, affected by customers’ inventory adjustments.

Profit : Operating loss was recorded due to reduced revenue from key overseas products.

## Sales by Business Segment

Blood Management & Cell Therapy： Although sales of Apheresis Kits for Europe increased, sales for North America and Blood Bags for Africa and Asia declined.

Dialysis: Sales related to the hemodialysis business for China decreased, but sales of AV Fistula Needles for North America and Europe remained solid, resulting in a slight overall increase.

## Sales by Region

North America: Although sales of AV Fistula Needles remained strong, sales of our main overseas product, Apheresis Kits, declined.

Europe: Sales of AV Fistula Needles and Blood Bags increased steadily.

# Highlights in Business Results

(unit: JPY million)

| | Apr. - Sep. 2024 Results | Apr. - Sep. 2025 | | Year - over - Year | |
|---|---|---|---|---|---|
| | | Previous Forecast | Results | Diff. | % |
| **Net sales** | 33,830 | 33,800 | 32,216 | (1,614) | (4.8)% |
| **Operating profit** | 155 | 350 | (19) | (174) | — |
| **Ordinary profit** | (118) | 300 | (46) | 71 | — |
| **Profit attributable to owners of parent** | (258) | 100 | (190) | 67 | — |

Net sales




Operating profit




Ordinary profit




Profit attributable to owners of parent



# Summary by segment (geographical area)

| | |
|---|---|
| **[Japan]** | Sales of Closed Drug Mixing/Infusion Systems and Dysphagia-related products continued to grow, but sales related to the hemodialysis business in China and Acute Blood Purification products decreased. Despite efforts to pass on price increases and streamline unprofitable items, profits declined due to increased labor costs, repair expenses, and higher selling expenses. |
| **[Singapore]** | Sales of Apheresis Kits for Europe remained steady, while orders for North America decreased due to customer inventory adjustments. Foreign exchange losses were limited, resulting in improved profitability. |

(unit: JPY million)

| | | Apr. - Sep. 2024 | Apr. - Sep. 2025 | Year - over - Year | |
|---|---|---|---|---|---|
| | | | | Diff. | % |
| Japan | Sales | 22,253 | 21,925 | (328) | (1.5)% |
| | Ordinary profit | 426 | 301 | (125) | (29.4)% |
| Singapore※ | Sales | 12,891 | 11,748 | (1,143) | (8.9)% |
| | Ordinary profit | (418) | (183) | 234 | ― |
| China | Sales | 1,956 | 2,064 | 107 | 5.5% |
| | Ordinary profit | (80) | 86 | 167 | ― |
| Philippines | Sales | 1,825 | 1,648 | (177) | (9.7)% |
| | Ordinary profit | (144) | (311) | (167) | ― |
| Germany | Sales | 2,041 | 2,088 | 47 | 2.3% |
| | Ordinary profit | 195 | 253 | 58 | 30.1% |
| Others※ | Sales | 2,427 | 2,911 | 484 | 19.9% |
| | Ordinary profit | (50) | (85) | (34) | ― |

※Singapore : This segment includes Indonesian subsidiary.
※Others : This segment includes business activity of subsidiaries in Japan, United States, South Korea , Thailand and Part of China.

# Sales by Business Segment

(unit: JPY million)

## Infusion & Nutrition


■ Apr. - Sep. 2024 ■ Apr. - Sep. 2025

Sales of Closed Drug Mixing/Infusion Systems and Dysphagia-related products increased, but a decline in Medical Gloves led to a slight overall decrease.

## Dialysis




■ Apr. - Sep. 2024 ■ Apr. - Sep. 2025

Sales related to the hemodialysis business for China decreased, but sales of AV Fistula Needles for North America and Europe remained steady, resulting in a slight overall increase.

## Cardiovascular




■ Apr. - Sep. 2024 ■ Apr. - Sep. 2025

Due to weaker demand, sales of Acute Blood Purification devices and Artificial Heart-Lung Circuits decreased.

## Blood Management & Cell Therapy


■ Apr. - Sep. 2024 ■ Apr. - Sep. 2025

Sales of Apheresis Kits for North America and Blood Bags for Africa and Asia decreased.

# Sales change by Region (Customer's Location)

In Europe, AV Fistula Needles performed well, leading to increased revenue. In Japan, Closed Drug Mixing/Infusion Systems and Dysphagia-related products also performed steadily. However, revenue decreased due to a decline in sales related to the hemodialysis business in China, along with lower sales of Apheresis Kits for North America.

(unit: JPY million)

| | Apr. - Sep. 2024 | Apr. - Sep. 2025 | Year - over - Year | | Sales composition |
|---|---|---|---|---|---|
| | | | Diff. | % | |
| Japan | 19,141 | 19,653 | 511 | 2.7% | 61.0% |
| Asia | 6,325 | 4,900 | (1,425) | (22.5)% | 15.2% |
| North America | 3,885 | 2,307 | (1,578) | (40.6)% | 7.2% |
| Europe | 3,232 | 4,315 | 1,082 | 33.5% | 13.4% |
| Others | 1,245 | 1,039 | (205) | (16.5)% | 3.2% |



# Ordinary profit : Compared with the previous year

A significant decline in gross profit, mainly due to lower sales of overseas flagship products such as Apheresis Kits and Blood Bags, had a major impact. However, profitability improved owing to a reduction in foreign exchange losses and equity in earnings of affiliates.

(unit: JPY million)

*The underlined figures exclude impact of exchange rate.




Exchange Rate (average during period) (unit: JPY)

| | US Dollar | Euro | Singapore Dollar |
|---|---|---|---|
| Apr. - Sep. 2024 | 152.63 | 164.60 | 114.16 |
| Apr. - Sep. 2025 | 146.04 | 162.15 | 113.00 |

# Forecast for FYE Mar. 2026

Based on the results for the six months ended September 30, 2025, we have revised the consolidated earnings forecast for the fiscal year ending March 31, 2026.

(unit: JPY million)

| | FYE Mar. 2025 Result | FYE Mar. 2026 Forecast | | Year - over - Year % |
|---|---|---|---|---|
| | | Previous Forecast | New Forecast | |
| **Net sales** | 69,749 | 68,000 | 66,000 | (5.4)% |
| **Operating profit** | 872 | 900 | 500 | (42.7)% |
| **Ordinary profit** | 514 | 600 | 300 | (41.7)% |
| **Profit attributable to owners of parent** | 89 | 200 | 100 | 11.7% |

＊Exchange rate for the forecast: 1USD=153yen, 1EUR=177yen, 1SGD=118yen.

Sales： Although a decrease in sales of overseas flagship products — Apheresis Kits and Hemodialysis devices for China — is expected, recovery in the second half is anticipated through continued growth in the Oncology and Nutrition fields in Japan.

Profit： While the earnings environment remains challenging due to reduced sales of overseas core products and increased selling expenses, we aim to improve profitability by promoting cost reductions and operational efficiency.

The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.